Navigation Links
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Date:4/30/2008

of $379,000 related to severance and litigation. In Q1 2007, the Company reported $13,000 of restructuring and impairment charges related to the relocation of our stent-graft manufacturing to our corporate headquarters.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, statements regarding the Company's financial guidance for 2008, the integration and performance of its 2007 acquisitions, the cost-cutting initiatives it has undertaken, the start-up of its French and Italian sales forces, enrollment in its UNITE stent graft clinical trial, and the launch of its EndoFit Thoracic Uniform TopStent are forward-looking statements involving risks and uncertainties. The Company's first quarter 2008 financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include, but are not limited to, the potential for encountering unfavorable foreign currency exchange rate fluctuations; risks related to product demand and market acceptance of the Company's products; the significant competition the Company faces from other companies, technologies, and alternative medical procedures; the Company's ability to realize the anticipated benefits of its acquisitions; the Company's ability to effectively expand its sales force; the Company's ability to realize significant cost savings through its cost-cutting initiatives; the possibility that the Company's new products may fail to provide the desired safety and effi
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
2. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
3. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
9. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
10. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/26/2015)... (PRWEB) , ... July 26, 2015 , ... ... of its VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA ... Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal delta” method ...
(Date:7/24/2015)... 2015 Equity Research Institute has ... (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ... Biotherapeutics Inc. (NASDAQ: NWBO ), and Acorda Therapeutics ... PDL BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI ... at 5,146.41, down 0.49%, the Dow Jones Industrial Average ...
(Date:7/24/2015)... 24, 2015 The global ... USD 27.8 billion by 2022, growing at an estimated ... a new study by Grand View Research, Inc. Development ... to result in significant reduction in cost of sequencing ... and usage rates of next generation sequencing throughout the ...
Breaking Biology Technology:Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5
... Elsevier, the,leading publisher of scientific, technical and ... has joined Elsevier Health Sciences as Vice,President, ... responsible for developing the overall content strategy ... of First Consult and derivative,products. , ...
... successful second funding period, the first three DFG Research ... another four years. This decision was made by the ... Foundation) at its spring session in Bonn. As a ... the Earth System" in Bremen, "The Center for Functional ...
... chemical contaminants in the airST. PETERSBURG, Fla., May 1 ... Board: ECET) announced today the initiation of a project ... utilizing its proven Pure Air Technology (PATI). The new ... from which all biological and chemical contaminants have been ...
Cached Biology Technology:Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource 2The first DFG research centers to be funded for another 4 years 2The first DFG research centers to be funded for another 4 years 3The first DFG research centers to be funded for another 4 years 4EClips Energy Technologies, Inc. To Develop New 'Sterile Air' Product Using PATI Technology 2EClips Energy Technologies, Inc. To Develop New 'Sterile Air' Product Using PATI Technology 3
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Sol